Chronic illness drug developer Sigilon Therapeutics, co-founded by MIT and UIC researchers, has filed to go public after raising almost $200m in funding.

Sigilon¬†Therapeutics, a US-based chronic illness therapy developer based on research primarily from Massachusetts Institute of Technology (MIT), has filed for a $100m initial public offering on the Nasdaq Global Market. Founded in 2015, Sigilon has built a drug development platform dubbed Shielded Living Therapeutics which it is using to create therapeutic molecules that can make…

The rest of this content is only accessible to Global University Venturing Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.